Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT05748834
This study is recruiting at 7 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: Learn how well the combination of tucatinib and Doxil works Learn more about the side effects of the combination of tucatinib and Doxil
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- SCRI Development Innovations, LLC
- Last updated on ClinicalTrials.gov
- March 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Maryland Oncology Hematology · Columbia, MD
Pennsylvania · 1
- Alliance Cancer Specialists · Bensalem, PA
Tennessee · 1
- SCRI Oncology Partners · Nashville, TN
Texas · 2
- Texas Oncology- DFW · Dallas, TX
- Texas Oncology- San Antonio · San Antonio, TX
Virginia · 2
- Virginia Oncology Associates · Norfolk, VA
- Blue Ridge Cancer Care (Oncology & Hematology Assoc of SW Virginia, Inc) · Salem, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.